IBD: Co-medication does not affect Results of Approval Studies

被引：0
|
作者：
Klein, Friederike
机构：
来源：
ZEITSCHRIFT FUR GASTROENTEROLOGIE | 2025年 / 63卷 / 02期
关键词：
D O I：
10.1055/a-2447-9225
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
In clinical Studies on Biologics or low-molecular-weight Active Substances, Participants with chronic inflammatory Bowel Disease (IBD) often receive other Drug Therapy in parallel with the Study Medication. An international Research Team with Lead Author Dhruv Ahuja from the Medical Clinic of the Indira Gandhi Hospital in New Delhi, India, examined whether this Concomitant Medication had an Influence on the Study Results
引用
收藏
页码：110 / 110
页数：1
相关论文
共 50 条
  • [21] CO-MEDICATION CONSIDERATIONS TO RATIONALIZE DRUG INTERACTION STRATEGIES
    Bloomer, Jackie
    DRUG METABOLISM REVIEWS, 2015, 47 : 10 - 10
  • [22] Coronary stent healing, endothelialisation and the role of co-medication
    van Beusekom, H. M.
    Schoemaker, R.
    Roks, A. J.
    Zijlstra, F.
    van der Giessen, W. J.
    NETHERLANDS HEART JOURNAL, 2007, 15 (11) : 395 - 396
  • [23] The combined contraceptive ring NuvaRing® and spermicide co-medication
    Haring, T
    Mulders, TMT
    CONTRACEPTION, 2003, 67 (04) : 271 - 272
  • [24] High prevalence of unknown co-medication in hospitalised patients
    Karin Rieger
    André Scholer
    Isabelle Arnet
    Frank T. Peters
    Hans H. Maurer
    Ingeborg Walter-Sack
    Walter E. Haefeli
    Meret Martin-Facklam
    European Journal of Clinical Pharmacology, 2004, 60 : 363 - 368
  • [25] The contraceptive vaginal ring, NuvaRing®, and antimycotic co-medication
    Verhoeven, CHJ
    van den Heuvel, MW
    Mulders, TMT
    Dieben, TOM
    CONTRACEPTION, 2004, 69 (02) : 129 - 132
  • [26] Age, comorbidity and hypertensive co-medication do not affect cardiovascular tolerability of 10 mg alfuzosin once daily
    Hartung, R
    Matzkin, H
    Alcaraz, A
    Emberton, M
    Harving, N
    van Moorselaar, J
    Elhilali, M
    Vallancien, G
    JOURNAL OF UROLOGY, 2006, 175 (02): : 624 - 628
  • [27] Co-medication prescription pattern and qualification of first prescribers of stimulant medication in The Netherlands
    de Jong-van den Berg, L. T.
    JOURNAL OF NEURAL TRANSMISSION, 2007, 114 (07) : LVII - LVII
  • [28] The comorbidity and co-medication profile of patients with progressive supranuclear palsy
    Greten, Stephan
    Wegner, Florian
    Jensen, Ida
    Krey, Lea
    Rogozinski, Sophia
    Fehring, Meret
    Heine, Johanne
    Doll-Lee, Johanna
    Poetter-Nerger, Monika
    Zeitzschel, Molly
    Hagena, Keno
    Pedrosa, David J.
    Eggers, Carsten
    Buerk, Katrin
    Trenkwalder, Claudia
    Claus, Inga
    Warnecke, Tobias
    Suess, Patrick
    Winkler, Juergen
    Gruber, Doreen
    Gandor, Florin
    Berg, Daniela
    Paschen, Steffen
    Classen, Joseph
    Pinkhardt, Elmar H.
    Kassubek, Jan
    Jost, Wolfgang H.
    Toenges, Lars
    Kuehn, Andrea A.
    Schwarz, Johannes
    Peters, Oliver
    Dashti, Eman
    Priller, Josef
    Spruth, Eike J.
    Krause, Patricia
    Spottke, Annika
    Schneider, Anja
    Beyle, Aline
    Kimmich, Okka
    Donix, Markus
    Haussmann, Robert
    Brandt, Moritz
    Dinter, Elisabeth
    Wiltfang, Jens
    Schott, Bjoern H.
    Zerr, Inga
    Baehr, Mathias
    Buerger, Katharina
    Janowitz, Daniel
    Perneczky, Robert
    JOURNAL OF NEUROLOGY, 2024, 271 (02) : 782 - 793
  • [29] Automating economic analysis of co-medication use in clinical trials
    Waldeck, R
    Kawabata, H
    Yuan, Y
    VALUE IN HEALTH, 2003, 6 (03) : 180 - 180
  • [30] Ziprasidone population pharmacokinetics and co-medication effects in Chinese patients
    Bao, Shuang
    Yang, Siyu
    Hua, Zixin
    Li, Jiqian
    Zang, Yannan
    Li, Xingang
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2024, 397 (12) : 9811 - 9821
12345